{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P49711",
      "entity_text" : "CTCF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pfam:PF08990",
      "entity_text" : "docking",
      "entity_type" : "family"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "For example, at CSNK1A1, a drug target in acute myeloid leukemia (AML) tumor cells, VEGFA, which is upregulated in many cancers, and RUNX1, a well defined oncogene in AML, the evidence suggests that super-enhancers in these cancer cells use a CTCF enhancer docking mechanism to interact with the oncogene.",
  "reading_complete" : "2020-08-08T17:01:43Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T17:00:31Z",
  "trigger" : "enhancer",
  "evidence" : [ "CTCF enhancer-docking" ],
  "pmc_id" : "5929158",
  "score" : 0
}